Dr. Kinga Hosszu is the co-director of the IDMS lab, where she provides scientific oversight, directs experimental and technical assay development, and facilitates scientific collaboration. Dr. Hosszu previously led a team at LakePharma Inc (now part of Curia) that focused on drug discovery, pharmacodynamics, regulation of signaling pathways, immunological response, and assay development. Her current research is focused on identifying predictive biomarker signatures for patients undergoing transplantation and cellular therapy. Dr. Hosszu earned her PhD degree in genetics from Stony Brook University where she also completed two postdoctoral fellowships in the area of immunology.